No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Work & Management
UK Markets close in 3 hrs 10 mins
Why companies are ditching dual listings
Shell and BHP are among big global firms to scrap secondary listings, Rio Tinto may do so too
Pharming Group N.V. (0QCO.L)
YHD - YHD Delayed price. Currency in USD
Add to watchlist
At close: 6:07PM EDT
213 reactions on $0QCO.L conversation
Sign in to post a message.
This is like buying a Lamborghini at the price of a Lada.
Julius Caesar - Renaissance
Decreasing revenue is usually a sign that a company is dying out.
About 1.2 cents per share profit in last quarter was also a decrease.
Possibly worth a look in a few years to see where the company is at to enter when nobody looks at it anymore.
The Big D
Its dead money stock is illiquid. Volume almost zero.
@ Tim's question to explain the downfall:Somehow the stock has been treated as a Pharma rather then the Biotech it (for the biggest part) is.Pharming reported growth in sales and revenue today where h1 is up 14% in revenue and 17% in profit... Q2 vs q1 however show a 21% decline in US sales (biggest market), this is due to pharmacies and patients building up inventory in Q1 and building it off again in q2... see this statement in the press release:"US revenues increased 13% year-on-year to #$%$85.0 million (H1 2019: #$%$75.0 million), however,sales in Q2 2020 declined by 21% compared to Q1 2020. This was as a result of an unusually highsales level towards the end of Q1 2020, which is believed to have included some pre-filling ofprescriptions in response to the emerging COVID-19 pandemic. The Company therefore believesthat the H1 2020 results are more representative of underlying performance, than either quarterin isolation"Fact remains that:* growth in revenue and profit for full year 2020 remains to be expected* Pharming uses it's profit to fund 100% of it's pipeline projects*next product launch Leniolisib is still scheduled H1 2022 and will double current revenue (or so I expect)*cov19 research is almost recruiting (any day now a press release can be expected)* blockbuster researches AKI and Pre eclampsia were delayed a bit due to covid19, however remain promising and in fact the cov19 research might underline the chance for success (cytokine storm)In a nutshell: strong buy especially for this price of little over 1 euro today, although Id'd still be buying for double the amount as well...
Today Pharming Group got a FDA approval to start the evaluation trial in phase 4 in regards to Ruconest treatment against Covid-19. Ahead of publishing results of the first two trials running in Europe and the US.
I don't think The U.S. IPO is happening, at least not today. It will be trading on the NASDAQ under the ticker symbol PHAR. l can always see IPOs on my trading platform well before they are set to trade publicly. I do not see it, I would assume they have postponed the IPO
To be expected, soon:
News about a covid medicine
listing on the Nasdaq.
To the moon this one!!
Leiden, The Netherlands, 10 December 2020: Pharming Group N.V. (“Pharming” or “the Company”)
(Euronext Amsterdam: PHARM) today announced that the first patient has been enrolled in a
randomised, open label, parallel group, controlled, pilot clinical trial in up to 120 patients hospitalised
with confirmed COVID-19 treated with RUCONEST® (recombinant human C1 inhibitor) for the
prevention of severe SARS-CoV-2 infections at the Valley Hospital in Ridgewood, New Jersey in the
Pharming reports encouraging results from use of RUCONEST® in COVID-19 patients
Pharming announces encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.
NEW Bank-analyst rating Pharming this morning.
Up by 350%, just days before FY results.
I am not sure if there any dutch people here, but i am and i have been an investor in Pharming for a long time. (several years now) If there are any questions concerning this company. Just ask me!
Ruconest in the prevention of ADRS.
NCT03576469 FDA trial Completed - Results Pending.
Could lead to a new and long awaited second Pharming indication.
Still two more weeks till you are to late.
Strong buy 🚀🚀🚀🚀
In the start of feb they can release a pb.
Hello traders, im from the netherlands and i would like to inform you about the movement of pharming.December 10 the board will make a decision about the listing for nasdaq.December 22 the listing will go live.What do we in the netherlands expect?- postive news on the covid medicine - a strong beat in q4 Expectation: #$%$2-3 What can go wrong?- no listing nasdaq- a slight step back in the covid medicineExpectation: #$%$0,80-0,90
I found this in a Dutch-stock -conversationgroup:
A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury
Anneza Panagiotou 1 , Marten Trendelenburg 2 , Ingmar A F M Heijnen 3 , Stephan Moser 1 , Leo H Bonati 4 , Tobias Breidthardt 1 , Gregor Fahrni 5 , Christoph Kaiser 5 , Raban Jeger 5 , Michael Osthoff 6
Objectives: This study sought to determine the efficacy profile and safety of recombinant human C1 esterase inhibitor (rhC1INH) in the prevention of contrast-associated acute kidney injury after elective coronary angiography.
Background: Contrast-associated acute kidney injury is caused by tubular cytotoxicity and ischemia/reperfusion injury. rhC1INH is effective in reducing renal ischemia/reperfusion injury in experimental models.
Methods: In this placebo-controlled, double-blind, single-center trial 77 patients with chronic kidney disease were randomized to receive 50 IU/kg rhC1INH before and 4 h after elective coronary angiography or placebo. The primary outcome was the peak change of urinary neutrophil gelatinase-associated lipocalin within 48 h, a surrogate marker of kidney injury.
Results: Median peak change of urinary neutrophil gelatinase-associated lipocalin was lower in the rhC1INH group (4.7 ng/ml vs. 22.5 ng/ml; p = 0.038) in the per-protocol population but not in the modified intention-to-treat analysis, and in patients with percutaneous coronary interventions (median, 1.8 ng/ml vs. 26.2 ng/ml; p = 0.039 corresponding to a median proportion peak change of 11% vs. 205%; p = 0.002). The incidence of a cystatin C increase =10% within 24 h was lower in the rhC1INH group (16% vs. 33%; p = 0.045), whereas the frequency of contrast-associated acute kidney injury was comparable. Adverse events during a 3-month follow-up were similarly distributed.
Conclusions: Administration of rhC1INH before coronary angiography may attenuate renal injury as reflected by urinary neutrophil gelatinase-associated lipocalin and cystatin C. The safety profile of rhC1INH was favorable in a patient population with multiple comorbidities. (Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects [PROTECT]; NCT02869347).
Keywords: contrast-induced acute kidney injury; coronary angiography; cystatin C; neutrophil gelatinase-associated lipocalin; recombinant C1 esterase inhibitor.
Impact of Mannose-Binding Lectin Deficiency on Radiocontrast-Induced Renal Dysfunction
Michael Osthoff 1 , Marten Trendelenburg 2
Free PMC article
Contrast-induced nephropathy (CIN) is the third leading cause of acute renal failure in hospitalized patients. Endothelial dysfunction, renal medullary ischemia, and tubular toxicity are regarded as the most important factors in the pathogenesis of CIN. Mannose-binding lectin (MBL), a pattern recognition protein of the lectin pathway of complement, has been found to aggravate and mediate tissue damage during experimental renal ischemia/reperfusion (I/R) injury which was alleviated by inhibition with C1 inhibitor, a potent MBL, and lectin pathway inhibitor. In this paper, we highlight the potential role of MBL in the pathogenesis of human CIN. In experimental I/R models, MBL was previously found to induce tubular cell death independent of the complement system. In addition, after binding to vascular endothelial cells, MBL and its associated serine proteases were able to trigger a proinflammatory reaction and contribute to endothelial dysfunction. In humans, urinary MBL was increased after administration of contrast media and in individuals with CIN. Moreover, individuals with normal/high MBL levels were at increased risk to develop radiocontrast-induced renal dysfunction. Hence, MBL and the lectin pathway seem to be a promising target given that a licensed, powerful, human recombinant inhibitor exits to be added to the scarce armamentarium currently available for prophylaxis of CIN.
Pharming Group Reports Interim Financial Results for the First Nine Months of 2018,
LEIDEN, Netherlands, October 25, 2018 /PRNewswire/ --
Compared with the first nine months of 2017 (on a like-for-like basis):
Product revenues up 74% to €97.7 million, operating profit up 144% to €31.0 million, net profit up 131% to 11.7 million
Compared with the last quarter ended 30 June 2018:
Product revenues up 30% to €38.6 million, operating profit up 82% to €14.7 million, net profit up 77% to €5.4 million
Cash increased to €72.2 million (after €7.5m repayment of debt) to invest in key growth drivers
Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
Net product sales for the first nine months of 2018 increased to €97.7 million (Q3: €38.6 million), an increase of approximately 74% on a like-for-like basis compared to €56.0 million for the first nine months of 2017), as a result of the increasing numbers of patients using RUCONEST® in the USA and in Europe.
US net product sales for the first nine months of 2018 increased to €92.9 million (Q3: €36.5 million), an increase of 77% compared to €52.5 million for the first nine months of 2017. In the rest of the world, product sales for the first nine months of 2018 increased to €4.8 million (Q3: €2.1 million), an increase of approximately 37% compared to €3.5 million the first nine months of 2017.
Total revenues for the first nine months of 2018 increased by 73% to €98.3 million (including €0.6 million of license revenue) from €56.7 million in the first nine months of 2017 (including €0.7 million in license revenue).
Operating profits rose by 144% to €31.0 million in the first nine months of 2018, compared to €12.7 million in the first nine months of 2017. Operating profits also rose by 82% quarter on quarter, to €14.7 million in the third quarter from €8.1 million in the second quarter of 2018. These improvements were made despite a considerable increase in operating costs, mainly relating to improvements in production capacity and development costs for the new indications and formulations of RUCONEST®.
Net profit for the first nine months was €11.7 million (Q3: €5.4 million), compared with a loss as originally stated of €37.7 million in the same period last year. The 77% improvement quarter on quarter resulted mainly from the improvement in sales in the USA.
Positive cashflows during the third quarter of 2018 were driven by increasing revenues above the cash required for costs and repayment of the first quarterly instalment of €7.5 million of the principal amount of the Company's outstanding loan including associated fees. This resulted in an increase in the cash position to €72.2 million from €66.9 million at June 30 2018 (€38.6 million at 30 September 2017).
Do i need to say more.....Goldmine !!
Goodmorning PHAR-holders. Monday 3/8/2021
SimplyWallstreet gives PHAR a value of $36.34
3 X the current position of $13.35 - WOW.
Cant wait till December 22nd when this great company enters Nasdaq stockmarket!!
Pharming Group (PHAR) reports record revenues and record cash.
Net income was tempered by a weak Dollar as expected.
Gives outlook regarding growing revenues for the rest of 2021,
and sees continued increase of income.
Tomorrow there is a Party over here, you all are invited .
DVLA tells drivers to avoid costly third-party services for licence applications
Yahoo Finance UK
Costly Airbus paint flaw goes wider than the Gulf
EU banks demand access to City markets in blow for Brussels
© 2021 Yahoo. All rights reserved.
About our ads